[go: up one dir, main page]

CR20200510A - Protreínas de fusión del factor de diferenciación de crecimiento 15 - Google Patents

Protreínas de fusión del factor de diferenciación de crecimiento 15

Info

Publication number
CR20200510A
CR20200510A CR20200510A CR20200510A CR20200510A CR 20200510 A CR20200510 A CR 20200510A CR 20200510 A CR20200510 A CR 20200510A CR 20200510 A CR20200510 A CR 20200510A CR 20200510 A CR20200510 A CR 20200510A
Authority
CR
Costa Rica
Prior art keywords
fusion proteins
differentiation factor
growth differentiation
gdf15
region
Prior art date
Application number
CR20200510A
Other languages
English (en)
Inventor
ELLISON Murielle Marie VENIANT
Yumei Xiong
Kenneth William Walker
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CR20200510A publication Critical patent/CR20200510A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>En el presente documento se proporcionan molécula de Fcs de GDF15. En algunas realizaciones, la molécula de Fc de GDF15 es una fusión GDF15-Fc, en la que se fusiona una región de GDF15 a una región de Fc. En algunas realizaciones, la región de GDF15 está fusionada a la región de Fc mediante un enlazador. También, en el presente documento se proporcionan métodos para crear y usar molécula de Fcs de GDF15.</p>
CR20200510A 2018-04-09 2019-04-08 Protreínas de fusión del factor de diferenciación de crecimiento 15 CR20200510A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862655108P 2018-04-09 2018-04-09
PCT/US2019/026369 WO2019199685A1 (en) 2018-04-09 2019-04-08 Growth differentiation factor 15 fusion proteins

Publications (1)

Publication Number Publication Date
CR20200510A true CR20200510A (es) 2020-11-26

Family

ID=66251865

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20200510A CR20200510A (es) 2018-04-09 2019-04-08 Protreínas de fusión del factor de diferenciación de crecimiento 15

Country Status (23)

Country Link
US (4) US12054527B2 (es)
EP (1) EP3773656A1 (es)
JP (2) JP7058670B2 (es)
KR (1) KR20200140878A (es)
CN (1) CN111954537A (es)
AR (1) AR114476A1 (es)
AU (1) AU2019253462A1 (es)
BR (1) BR112020020823A2 (es)
CA (1) CA3096097A1 (es)
CL (1) CL2020002585A1 (es)
CO (1) CO2020012563A2 (es)
CR (1) CR20200510A (es)
EA (1) EA202092419A1 (es)
IL (1) IL277842A (es)
JO (1) JOP20200258A1 (es)
MA (1) MA52205A (es)
MX (1) MX2020010659A (es)
PE (1) PE20201350A1 (es)
PH (1) PH12020551655A1 (es)
SG (1) SG11202009884YA (es)
TW (1) TW202003586A (es)
UY (1) UY38177A (es)
WO (1) WO2019199685A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017152105A1 (en) * 2016-03-04 2017-09-08 Ngm Biopharmaceuticals, Inc. Compositions and methods for modulating body weight
WO2019199685A1 (en) 2018-04-09 2019-10-17 Amgen Inc. Growth differentiation factor 15 fusion proteins
WO2020185533A1 (en) * 2019-03-08 2020-09-17 Amgen Inc. Growth differentiation factor 15 combination therapy
AU2020260931B2 (en) * 2019-04-23 2023-08-24 Lg Chem, Ltd. Fusion polypeptide comprising Fc region of immunoglobulin and GDF15
WO2021139763A1 (zh) * 2020-01-08 2021-07-15 上海翰森生物医药科技有限公司 Fgf21突变体蛋白及其融合蛋白
WO2022092915A1 (ko) * 2020-10-30 2022-05-05 가톨릭대학교 산학협력단 Gdf15를 유효성분으로 함유하는 면역질환의 예방 및 치료용 조성물
US20240350588A1 (en) * 2021-08-24 2024-10-24 Sunshine Lake Pharma Co., Ltd. Gdf15 fusion proteins and use thereof
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
AU8591198A (en) 1997-07-31 1999-02-22 Johns Hopkins University School Of Medicine, The Growth differentiation factor-15
ID30327A (id) 1999-01-07 2001-11-22 Lexigen Pharm Corp EKSPRESI DAN EKSPOR PROTEIN-PROTEIN ANTI OBESITAS SEBAGAI PROTEIN-PROTEIN FUSI Fc
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US20030103978A1 (en) 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
ES2311560T3 (es) 2000-12-07 2009-02-16 Eli Lilly And Company Proteinas de fusion glp-1.
EP1395605B8 (en) 2001-03-09 2014-12-17 Iterative Therapeutics, Inc. Polymeric immunoglobulin fusion proteins that target low-affinity fcgamma receptors
JP4422949B2 (ja) 2001-06-26 2010-03-03 武田薬品工業株式会社 ＴＧＦ−βスーパーファミリー産生・分泌促進剤
US7332474B2 (en) 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
US7101852B2 (en) 2003-05-30 2006-09-05 The Board Of Regents Of The University Of Texas System Composition and method for treatment and prevention of restenosis
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
CN108743967B (zh) 2003-11-13 2022-04-26 韩美科学株式会社 含有免疫球蛋白fc区作为载体的药物组合物
WO2005077981A2 (en) 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
PT2929891T (pt) 2004-04-13 2020-04-08 St Vincents Hospital Sydney Ltd Método para modulação do apetite
WO2005113585A2 (en) 2004-05-20 2005-12-01 Acceleron Pharma Inc. Modified tgf-beta superfamily polypeptides
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
EP1931709B1 (en) 2005-10-03 2016-12-07 Xencor, Inc. Fc variants with optimized fc receptor binding properties
CN1974601A (zh) 2005-11-28 2007-06-06 上海新生源医药研究有限公司 一种新型Fc融合蛋白及其生产方法
US8629244B2 (en) 2006-08-18 2014-01-14 Ablynx N.V. Interleukin-6 receptor binding polypeptides
US20100278843A1 (en) 2007-08-16 2010-11-04 St. Vincent's Hospital Sydney Limited Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity
PT2235064E (pt) 2008-01-07 2016-03-01 Amgen Inc Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática
WO2009141357A1 (en) 2008-05-20 2009-11-26 Roche Diagnostics Gmbh Gdf-15 as biomarker in type 1 diabetes
JP5787757B2 (ja) 2008-08-04 2015-09-30 ファイブ プライム セラピューティックス インコーポレイテッド Ｆｇｆｒ細胞外ドメイン酸性領域突然変異タンパク質
EP2350669B9 (en) 2008-10-31 2014-06-11 St Vincent's Hospital Sydney Limited Methods of prognosis in chronic kidney disease
US9200060B2 (en) 2009-11-23 2015-12-01 Amgen Inc. Monomeric antibody Fc
WO2011064758A2 (en) 2009-11-30 2011-06-03 Pfizer Limited Fusion protein
WO2011068893A1 (en) 2009-12-02 2011-06-09 Amgen Inc. BINDING PROTEINS THAT BIND TO HUMAN FGFR1C, HUMAN β-KLOTHO AND BOTH HUMAN FGFR1C AND HUMANβ-KLOTHO
US8362210B2 (en) 2010-01-19 2013-01-29 Xencor, Inc. Antibody variants with enhanced complement activity
CA2804351A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
EP2593428B1 (en) 2010-07-12 2014-11-19 Pfizer Limited N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
JP2013531030A (ja) 2010-07-12 2013-08-01 ファイザー・リミテッド 電位開口型ナトリウムチャネルの阻害剤としてのｎ−スルホニルベンズアミド
ES2534921T3 (es) 2010-08-26 2015-04-30 F. Hoffmann-La Roche Ag Uso de biomarcadores en la evaluación de la transición temprana de la hipertensión arterial a la insuficiencia cardíaca
EP2439535A1 (en) 2010-10-07 2012-04-11 F. Hoffmann-La Roche AG Diagnosis of diabetes related heart disease and GDF-15 and Troponin as predictors for the development of type 2 diabetes mellitus
CN108341868B (zh) 2010-11-05 2022-06-07 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
JP5972915B2 (ja) 2011-03-16 2016-08-17 アムジエン・インコーポレーテツド Ｆｃ変異体
CN103533951B (zh) 2011-04-08 2017-04-19 安姆根有限公司 使用生长分化因子15(gdf‑15)治疗或改善代谢障碍的方法
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
EP2807266B1 (en) 2012-01-26 2020-01-15 Amgen Inc. Growth differentiation factor 15 (gdf-15) polypeptides
WO2013148117A1 (en) 2012-03-27 2013-10-03 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
SG10201913376XA (en) 2012-04-20 2020-02-27 Merus Nv Methods and means for the production of ig-like molecules
MX370720B (es) 2012-12-21 2019-12-20 Aveo Pharmaceuticals Inc Anticuerpos anti-gdf15.
EP2950807B1 (en) * 2013-01-30 2018-03-28 NGM Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
NZ754961A (en) 2013-07-31 2022-04-29 Amgen Inc Growth differentiation factor 15 (gdf-15) constructs
EP3157942B1 (en) 2014-06-23 2020-06-17 Novartis AG Site specific protein modifications
WO2015198199A1 (en) 2014-06-23 2015-12-30 Novartis Ag Hsa-gdf-15 fusion polypeptide and use thereof.
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
TW201613958A (en) 2014-06-24 2016-04-16 Novo Nordisk As MIC-1 fusion proteins and uses thereof
KR20170065026A (ko) 2014-07-30 2017-06-12 엔지엠 바이오파마슈티컬스, 아이엔씨. 대사 장애 치료용으로 이용되는 조성물 및 방법
ES2799503T3 (es) 2014-10-31 2020-12-18 Ngm Biopharmaceuticals Inc Composiciones y procedimientos de uso para el tratamiento de trastornos metabólicos
EP3393494A1 (en) * 2015-12-22 2018-10-31 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
WO2017152105A1 (en) 2016-03-04 2017-09-08 Ngm Biopharmaceuticals, Inc. Compositions and methods for modulating body weight
US10336812B2 (en) 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
MX2018014023A (es) 2016-05-24 2019-04-04 Novo Nordisk As Compuestos de citocina inhibidora de macrofagos 1 (mic-1) y uso de estos.
TWI724392B (zh) 2018-04-06 2021-04-11 美商美國禮來大藥廠 生長分化因子15促效劑化合物及其使用方法
WO2019199685A1 (en) 2018-04-09 2019-10-17 Amgen Inc. Growth differentiation factor 15 fusion proteins
WO2020185533A1 (en) 2019-03-08 2020-09-17 Amgen Inc. Growth differentiation factor 15 combination therapy

Also Published As

Publication number Publication date
IL277842A (en) 2020-11-30
SG11202009884YA (en) 2020-11-27
CO2020012563A2 (es) 2020-10-30
US11161889B2 (en) 2021-11-02
CL2020002585A1 (es) 2020-12-04
TW202003586A (zh) 2020-01-16
KR20200140878A (ko) 2020-12-16
CN111954537A (zh) 2020-11-17
WO2019199685A1 (en) 2019-10-17
PH12020551655A1 (en) 2021-07-26
US20240327481A1 (en) 2024-10-03
PE20201350A1 (es) 2020-11-30
UY38177A (es) 2019-07-31
US20210147500A1 (en) 2021-05-20
AU2019253462A1 (en) 2020-11-26
MA52205A (fr) 2021-02-17
BR112020020823A2 (pt) 2021-01-19
EA202092419A1 (ru) 2021-02-05
JP2020533271A (ja) 2020-11-19
JP7058670B2 (ja) 2022-04-22
JOP20200258A1 (ar) 2020-10-11
US12054527B2 (en) 2024-08-06
US20230143988A1 (en) 2023-05-11
JP2022095856A (ja) 2022-06-28
EP3773656A1 (en) 2021-02-17
CA3096097A1 (en) 2019-10-17
MX2020010659A (es) 2020-10-28
US20220017584A1 (en) 2022-01-20
AR114476A1 (es) 2020-09-09

Similar Documents

Publication Publication Date Title
CR20200510A (es) Protreínas de fusión del factor de diferenciación de crecimiento 15
MX2021010737A (es) Terapia de combinacion por factor de diferenciacion del crecimiento 15.
MX2018013784A (es) Proteinas de fusion gdf15 y usos de estas.
EA202090216A2 (ru) Связывающие сывороточный альбумин домены фибронектина iii типа
MY193354A (en) Anti-vegf protein compositions and methods for producing the same
WO2021041715A3 (en) Compositions including igg fc mutations and uses thereof
EP3539982A3 (en) Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
SG10201808523RA (en) Il-22 polypeptides and il-22 fc fusion proteins and methods of use
ATE509032T1 (de) Chimerizierte gm-csf antikörper
WO2008114149A3 (en) Respiratory syncytial virus (rsv) chimeric polypeptide comprising the g protein central region domain located in between the f2 and f1 fusion protein domains
MX389073B (es) Método para producir una proteína de fusión de anticuerpo.
WO2019056023A3 (en) Claudin6 antibodies and methods of treating cancer
MX2023010640A (es) Péptidos neoantigénicos transmembranales.
MX2023001595A (es) Proteinas de fusion que comprenden proteinas de leche y composiciones de las mismas.
MX2020001223A (es) Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de estas.
SG10201903142RA (en) Serpin fusion polypeptides and methods of use thereof
BR112017017609A2 (pt) proteína de fusão fc, e, composição farmacêutica.
CL2021002757A1 (es) Polipéptido de fusión que comprende región fc de inmunoglobulina y gdf15.
AU2018226215B2 (en) Immunoconjugates with optimized linkers and orientation
PH12020550732A1 (en) Modified norovirus vp1 proteins and vlps comprising modified norovirus vp1 proteins
DK2059525T3 (da) Split-core-partikler til præsentation af fremmedmolekyler, især til vaccineanvendelser, og fremgangsmåde til fremstilling af disse
EA201792274A1 (ru) Слитые молекулы вариант iii рецептора эпидермального фактора роста-мезотелин и способы их применения
DE69232945D1 (de) BLUTPLAETTCHEN-GPIIIa P1A1 und -P1A2-EPITOPE, IHRE HERSTELLUNG UND VERWENDUNG
EP4397682A3 (en) Cell culture methods
MX2018003445A (es) Expresion de proteinas que contienen fc.